<?xml version='1.0' encoding='utf-8'?>
<document id="30968457"><sentence text="SSRI co-medication with NOAC or VKA does not increase hospitalisation for bleeding: A retrospective nationwide cohort study in Austria 2010-2015."><entity charOffset="24-28" id="DDI-PubMed.30968457.s1.e0" text="NOAC" /></sentence><sentence text="Non-vitamin K oral anticoagulants (NOACs) or vitamin K antagonists (VKAs) are used for the prophylaxis and treatment of thromboembolic events"><entity charOffset="4-13" id="DDI-PubMed.30968457.s2.e0" text="vitamin K" /><entity charOffset="45-54" id="DDI-PubMed.30968457.s2.e1" text="vitamin K" /><entity charOffset="35-43" id="DDI-PubMed.30968457.s2.e2" text="NOAC" /><pair ddi="false" e1="DDI-PubMed.30968457.s2.e0" e2="DDI-PubMed.30968457.s2.e0" /><pair ddi="false" e1="DDI-PubMed.30968457.s2.e0" e2="DDI-PubMed.30968457.s2.e2" /><pair ddi="false" e1="DDI-PubMed.30968457.s2.e0" e2="DDI-PubMed.30968457.s2.e1" /><pair ddi="false" e1="DDI-PubMed.30968457.s2.e2" e2="DDI-PubMed.30968457.s2.e2" /><pair ddi="false" e1="DDI-PubMed.30968457.s2.e2" e2="DDI-PubMed.30968457.s2.e1" /></sentence><sentence text=" A potential drug-drug interaction and increased bleeding events have been reported with co-medication of selective serotonin receptor inhibitors (SSRIs) and VKA"><entity charOffset="116-125" id="DDI-PubMed.30968457.s3.e0" text="serotonin" /></sentence><sentence text=" The aim of this study was to investigate the bleeding risk of a coprescription of NOAC or VKA with SSRI"><entity charOffset="83-87" id="DDI-PubMed.30968457.s4.e0" text="NOAC" /></sentence><sentence text="" /><sentence text="Patients with prescription of NOAC or VKA and an antidepressant drug therapy (ADTx) were selected from the drug reimbursement database of 13 Austrian health insurance funds"><entity charOffset="30-34" id="DDI-PubMed.30968457.s6.e0" text="NOAC" /></sentence><sentence text=" For this cohort, hospital discharge diagnoses for gastrointestinal bleeding, cerebral haemorrhage, and bleeding anaemia between 2010 and 2015 were analysed" /><sentence text="" /><sentence text="Data were available from 50 196 female and 31 308 male patients" /><sentence text=" Among these, 892 patients had 987 hospitalisations with bleeding events" /><sentence text=" The most frequent bleeding cases were gastrointestinal bleedings with 588 events (59" /><sentence text="6%), followed by cerebral haemorrhage with 344 (34" /><sentence text="8%), and bleeding anaemia with 55 events (5" /><sentence text="6%), respectively" /><sentence text=" The risk of bleeding events was similar between SSRI and other ADTx, when combined with oral anticoagulants (p = 0" /><sentence text="51)" /><sentence text=" Concomitant treatment of patients with SSRI or other ADTx and NOAC was associated with an increased bleeding risk compared with cotreatment with VKA (1"><entity charOffset="63-66" id="DDI-PubMed.30968457.s17.e0" text="NOAC" /></sentence><sentence text="21, 95% CI: 1" /><sentence text="05-1" /><sentence text="40; p = 0" /><sentence text="0097)" /><sentence text="" /><sentence text="Co-medication of SSRI with VKA or NOAC has little if any impact on hospital discharge diagnoses for bleeding events compared with cotreatment of those anticoagulants with other antidepressant medications"><entity charOffset="27-30" id="DDI-PubMed.30968457.s23.e0" text="VKA" /><entity charOffset="34-38" id="DDI-PubMed.30968457.s23.e1" text="NOAC" /><pair ddi="false" e1="DDI-PubMed.30968457.s23.e0" e2="DDI-PubMed.30968457.s23.e0" /><pair ddi="false" e1="DDI-PubMed.30968457.s23.e0" e2="DDI-PubMed.30968457.s23.e1" /></sentence><sentence text="" /></document>